ArticleBritish journal of haematology2020
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
Article in British journal of haematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 57 citations in OpenAlex.
- Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.Haematologica · 2026Review
- Efficacy and safety analysis of a novel BTK inhibitor in patients with mantle cell lymphoma harboring TP53 mutations.American journal of cancer research · 2026Article
- Secondary Genetic Events and Their Relationship toCancers · 2025Article
- Mantle cell lymphoma transformation to CD19-negative classic Hodgkin lymphoma as a novel mechanism of escape from CD19 chimeric antigen receptor T cell therapy.Journal of hematopathology · 2025Article
- Article
- Article
- Correlation between TP53 mutational status and digital quantification of p53 immunohistochemistry in mantle cell lymphoma.Virchows Archiv : an international journal of pathology · 2025Article
- The TP53 tumor suppressor gene: From molecular biology to clinical investigations.Journal of internal medicine · 2025Review
- Risk Assessment With Ultra-Low-Pass Whole-Genome Sequencing of Cell-Free DNA for Large B-Cell Lymphoma.JCO precision oncology · 2025Article
- Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target.Hematological oncology · 2025Review
- Review
- Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.Theranostics · 2025Article
- Your chemo is no good here: management of high-risk MCL.Hematology. American Society of Hematology. Education Program · 2024Review
- To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL.Hematology. American Society of Hematology. Education Program · 2024Review
- Article
- Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.Virchows Archiv : an international journal of pathology · 2024Article
- Utility of p53 Immunohistochemical Staining for Risk Stratification of Mantle Cell Lymphoma.Journal of hematology · 2024Article
- CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression.Blood advances · 2024Article
- MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation andHaematologica · 2024Article
- Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 4 countries.
Funding
Abstract
Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in recent years. However, patients carrying mutations in tumour protein p53 (TP53) do not benefit from modern chemotherapy-based treatments and have poor prognosis. Thus, there is a clinical need to identify missense mutations through routine analysis to enable patient stratification. Sequencing is not widely implemented in clinical practice for MCL, and immunohistochemistry (IHC) is a feasible alternative to identify high-risk patients. The aim of the present study was to investigate the accuracy of p53 as a tool to identify patients with TP53 missense mutations and the prognostic impact of overexpression and mutations in a Swedish population-based cohort. In total, 317 cases were investigated using IHC and 255 cases were sequenced, enabling analysis of p53 and TP53 status among 137 cases divided over the two-cohort investigated. The accuracy of predicting missense mutations from protein expression was 82%, with sensitivity at 82% and specificity at 100% in paired samples. We further show the impact of p53 expression and TP53 mutations on survival (hazard ratio of 3·1 in univariate analysis for both), and the association to risk factors, such as high MCL International Prognostic Index, blastoid morphology and proliferation, in a population-based setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.